Intranasal COVID vaccine: Bharat Biotech to launch iNCOVACC on January 26

Written by MD Bureau Published On 2023-01-23T11:15:24+05:30 | Updated On 23 Jan 2023 5:47 AM GMT

Intranasal COVID vaccine: Bharat Biotech to launch iNCOVACC on January 26

INCOVACC is a nasal vaccine indicated for active immunization against SARS-CoV-2 virus infection.

Bhopal: Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC on January 26, the company's CMD Krishna Ella announced. The vaccine manufacturer had already received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India.INCOVACC is a nasal vaccine indicated for active immunization...

Bhopal: Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC on January 26, the company's CMD Krishna Ella announced.

The vaccine manufacturer had already received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India.

INCOVACC is a nasal vaccine indicated for active immunization against SARS-CoV-2 virus infection.

"Our nasal vaccine will be officially launched on Republic Day on January 26," said Ella while participating in a session during the 8th edition of the India International Science Festival (IISF) that began at the Maulana Azad National Institute of Technology (MANIT), here on Saturday.

The session was titled 'Face-to-Face with New Frontiers in Science'.

The company had earlier announced that it would price the intranasal vaccine at Rs 325 per shot for procurement by the government, and 800 per shot for private vaccination centres.

As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune system of the nasal mucosa. Thus, intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection, and transmission.

The nasal vaccine can be taken after six months of the second dose.

An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.

COVID-19 disease iscaused by a Coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 may experience wide range of symptoms from mild to severe category. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; loss of taste or smell of recent onset; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

COVID 19coronaviruscoronavirus vaccineBharat Biotechbharat biotech newskrishna ellaiNCOVACCCentral Drugs Standard Control OrganisationCDSCOintranasal coronavirus vaccineIndia International Science Festival

Source : with inputs

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.